Valuation : MacroGenics, Inc.

Market Cap 255M 220M 208M 188M 353M 24.34B 355M 2.47B 949M 12.38B 957M 936M 39.13B P/E 2026 *
-2.57x
P/E 2027 * -2.44x
Enterprise Value 255M 220M 208M 188M 353M 24.34B 355M 2.47B 949M 12.38B 957M 936M 39.13B EV / Sales 2026 *
2.36x
EV / Sales 2027 * 2.81x
Free-Float
96.52%
Yield 2026 *
-
Yield 2027 * -
1 day+0.76%
1 week-9.09%
Current month+0.25%
1 month-0.50%
3 months+1.01%
6 months+28.21%
Current year+148.45%
1 week 3.9
Extreme 3.9
4.43
1 month 3.78
Extreme 3.785
4.49
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
28.09
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap. Importance
19/08/26 Sell

General Counsel

-31,105 0.0489%
17/08/26 Exercice

Chief Technology Officer

80,000 0.1259%
19/05/26 Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-9.09%+151.57%-19.03% 255M
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.19%-3.56%+42.74%+220.82% 27.07B
Weighted average by Cap. -0.56%-2.83%+31.37%+170.48%

Financials

2026 *2027 *
Net sales 108M 93.22M 88.27M 80.01M 150M 10.34B 151M 1.05B 403M 5.26B 406M 397M 16.62B 90.61M 78.07M 73.92M 67M 126M 8.66B 126M 878M 338M 4.4B 340M 333M 13.92B
Net income -88.7M -76.42M -72.36M -65.59M -123M -8.47B -124M -859M -330M -4.31B -333M -326M -13.62B -138M -119M -113M -102M -192M -13.19B -193M -1.34B -514M -6.71B -519M -507M -21.21B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
11/09/26 $4.000 +0.76% 381,932
10/09/26 $3.970 -3.41% 434,784
09/09/26 $4.110 -4.86% 599,225
08/09/26 $4.320 -1.82% 419,588
04/09/26 $4.400 +3.53% 442,785
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.000USD
Average target price
8.000USD
Spread / Average Target
+100.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!